Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM)

Article2015

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Sagar Lonial, Meletios A Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Philippe Moreau, María‐Victoria Mateos, Hila Magen, Andrew R. Belch, Donna Reece, Meral Beksaç, Andrew Spencer, Heather Oakervee, Robert Z. Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Ka Lung Wu, Anil Singhal, Jesús F. San Miguel, Morio Matsumoto, Jessica Katz, Eric Bleickardt, Valerie Poulart, Kenneth C. Anderson, Paul G. Richardson

Article2020

Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma

Xiaoyu Yan, Xu Steven Xu, Katja Weisel, María‐Victoria Mateos, Pieter Sonneveld, Meletios A Dimopoulos, Saad Z. Usmani, Nizar J. Bahlis, Thomas A. Puchalski, Jon Ukropec, Kevin M. Bellew, Ming Qi, Steven Sun, Honghui Zhou

Article2015

ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial, Meletios A Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Philippe Moreau, María‐Victoria Mateos, Hila Magen‐Nativ, Andrew R. Belch, Donna Reece, Meral Beksaç, Masafumi Taniwaki, Christoph Röllig, Anil Singhal, Jessica Katz, Eric Bleickardt, Valerie Poulart, Paul G. Richardson

Article2018

Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial, Meletios A Dimopoulos, Katja Weisel, Darrell White, Philippe Moreau, María‐Victoria Mateos, Jesús F. San Miguel, Kenneth C. Anderson, Ofer Shpilberg, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, Andrew R. Belch, Donna Reece, Meral Beksaç, Suresh G. Shelat, Oumar Sy, Anil Singhal, Paul G. Richardson

Article2020

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Ajay K. Nooka, Keith Stockerl‐Goldstein, Rafat Abonour, Ryan Ramaekers, Amit Khot, Adam Forbes, Cindy Lee, Bradley Augustson, Andrew Spencer, María‐Victoria Mateos, Bikramjit Chopra, Rachel Rogers, Deborah A. Smith, Jacqueline Davidge, Rocío Montes de, Geraldine Ferron‐Brady, Anne Yeakey, Mala K. Talekar, Brandon E. Kremer, Ira Gupta,

Discussion(0)

Related publications